Laverock Therapeutics to demonstrate at the European Society of Gene & Cell Therapy

• Laverock Therapeutics to demonstrate breadth of therapeutic applications of gene silencing platform at ESGCT

The Laverock Therapeutics team will be presenting a series of posters at the European Society of Gene & Cell Therapy (ESGCT) Annual Congress in Brussels next week. The posters will focus on the therapeutic applications of Gene Editing induced Gene Silencing (GEiGS®) technology, demonstrating the wide range of therapy areas that can benefit from its use.

The posters being presented by Laverock will be themed across three different sessions of Immunotherapy & CART cells, Metabolic diseases and Gene editing. These sessions will be on for Immunotherapy & CART cells – Engineering programmable, TME-responsive macrophages for solid tumour immunotherapy using Gene Editing induced Gene Silencing (GEiGS) technology. For Metabolic diseases – Next generation, allogeneic cell therapies for Type 1 Diabetes – utilising Gene Editing induced Gene Silencing (GEiGS) technology to address current challenges. For Gene editing – Gene Editing induced Gene Silencing (GEiGS) – A new platform for programmable cell engineering.